{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:19:01Z","timestamp":1787239141640,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["2017122"],"award-info":[{"award-number":["2017122"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["2017100"],"award-info":[{"award-number":["2017100"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["182632"],"award-info":[{"award-number":["182632"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["214972"],"award-info":[{"award-number":["214972"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["SP142"],"award-info":[{"award-number":["SP142"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005366","name":"Universitetet i Oslo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.breast.2026.104704","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:20:00Z","timestamp":1768868400000},"page":"104704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0310-5313","authenticated-orcid":false,"given":"K.G.","family":"Svalheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-1368","authenticated-orcid":false,"given":"N.K.","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bjerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gilje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.H.","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Naume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kaasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-3694","authenticated-orcid":false,"given":"J.A.","family":"Kyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.breast.2026.104704_bib1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.breast.2026.104704_bib2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.breast.2026.104704_bib3","doi-asserted-by":"crossref","first-page":"102352","DOI":"10.1016\/j.ctrv.2022.102352","article-title":"Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: a systematic review and meta-analysis","volume":"104","author":"Villacampa","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.breast.2026.104704_bib4","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1158\/1078-0432.CCR-19-3545","article-title":"FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1","volume":"26","author":"Narayan","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.breast.2026.104704_bib5","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2026.104704_bib6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104704_bib7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","article-title":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","volume":"35","author":"Dent","year":"2024","journal-title":"Ann Oncol"},{"issue":"10265","key":"10.1016\/j.breast.2026.104704_bib8","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cescon","year":"2020","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.breast.2026.104704_bib9","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104704_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221086916","article-title":"Emerging treatment strategies for metastatic triple-negative breast cancer","volume":"14","author":"Huppert","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104704_bib11","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2005.07.030","article-title":"Goals of treatment for patients with metastatic breast cancer","volume":"33","author":"Smith","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.breast.2026.104704_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2022.10.003","article-title":"Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer","volume":"178","author":"Loibl","year":"2023","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.breast.2026.104704_bib13","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1038\/s41591-022-02126-1","article-title":"Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial","volume":"28","author":"R\u00f8ssevold","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104704_bib14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12967-020-02424-7","article-title":"ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer","volume":"18","author":"Kyte","year":"2020","journal-title":"J Transl Med"},{"issue":"10","key":"10.1016\/j.breast.2026.104704_bib15","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.3944","article-title":"Natural and therapy-induced immunosurveillance in breast cancer","volume":"21","author":"Kroemer","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.breast.2026.104704_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.breast.2026.104704_bib17","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.breast.2026.104704_bib18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.breast.2026.104704_bib19","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm.2883","article-title":"Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival","volume":"18","author":"Walter","year":"2012","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.breast.2026.104704_bib20","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","article-title":"What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials","volume":"32","author":"Kotronoulas","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104704_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40268-024-00478-2","article-title":"The importance of patient reported outcomes in oncology clinical trials and clinical practice to inform regulatory and healthcare decision-making","volume":"24","author":"Bellino","year":"2024","journal-title":"Drugs R&D"},{"issue":"9","key":"10.1016\/j.breast.2026.104704_bib22","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","article-title":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline","volume":"33","author":"Di Maio","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104704_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102751","article-title":"Toxicity of immunotherapy combinations with chemotherapy across tumor indications: current knowledge and practical recommendations","volume":"127","author":"Rached","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.breast.2026.104704_bib24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.annonc.2020.02.003","article-title":"Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer","volume":"31","author":"Adams","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104704_bib25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/jnci\/djad240","article-title":"Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355","volume":"116","author":"Cescon","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104704_bib26","series-title":"Addendum to the EORTC QLQ-C30 scoring manual: scoring of the EORTC QLQ-C15-PAL","author":"Groenvold","year":"2006"},{"issue":"1","key":"10.1016\/j.breast.2026.104704_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2005.06.022","article-title":"The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care","volume":"42","author":"Groenvold","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104704_bib28","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3389\/fpsyg.2020.01502","article-title":"\"Honorable Toward Your Whole Self\": experiences of the body in fatigued breast cancer survivors","volume":"11","author":"Penner","year":"2020","journal-title":"Front Psychol"},{"issue":"2","key":"10.1016\/j.breast.2026.104704_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0022-3999(93)90081-P","article-title":"Development of a fatigue scale","volume":"37","author":"Chalder","year":"1993","journal-title":"J Psychosom Res"},{"issue":"6","key":"10.1016\/j.breast.2026.104704_bib30","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41591-024-02929-4","article-title":"Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer","volume":"30","author":"Zeng","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.breast.2026.104704_bib31","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1038\/s41591-023-02631-x","article-title":"Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma","volume":"29","author":"Fraterman","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104704_bib32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41523-022-00457-3","article-title":"Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer","volume":"8","author":"Barrios","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"6","key":"10.1016\/j.breast.2026.104704_bib33","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104704_bib34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12967-020-02424-7","article-title":"ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer","volume":"18","author":"Kyte","year":"2020","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104704_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007990","article-title":"Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial","volume":"12","author":"Andresen","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104704_bib36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.breast.2026.104704_bib37","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104704_bib38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1158\/1078-0432.CCR-21-2182","article-title":"A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors (DART, SWOG S1609)","volume":"28","author":"Adams","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.breast.2026.104704_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100257","article-title":"Refining patient selection for breast cancer immunotherapy: beyond PD-L1","volume":"6","author":"Kossai","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104704_bib40","article-title":"Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer","author":"Ullern","year":"2024","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104704_bib41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41523-024-00638-2","article-title":"Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation","volume":"10","author":"Chauhan","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"5","key":"10.1016\/j.breast.2026.104704_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100588","article-title":"Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment","volume":"7","author":"Aamdal","year":"2022","journal-title":"ESMO Open"},{"issue":"20","key":"10.1016\/j.breast.2026.104704_bib43","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1158\/0008-5472.CAN-17-0546","article-title":"beta-Adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy","volume":"77","author":"Bucsek","year":"2017","journal-title":"Cancer Res"},{"issue":"6\u20137","key":"10.1016\/j.breast.2026.104704_bib44","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/07357907.2021.1943746","article-title":"Chronic psychological stress attenuates the efficacy of anti-PD-L1 immunotherapy for bladder cancer in immunocompetent mice","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Invest"},{"issue":"9","key":"10.1016\/j.breast.2026.104704_bib45","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41591-019-0566-4","article-title":"Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity","volume":"25","author":"Yang","year":"2019","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.breast.2026.104704_bib46","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41574-019-0228-0","article-title":"The human stress response","volume":"15","author":"Russell","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.breast.2026.104704_bib47","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2005.04.010","article-title":"Item response theory was used to shorten EORTC QLQ-C30 scales for use in palliative care","volume":"59","author":"Petersen","year":"2006","journal-title":"J Clin Epidemiol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:28:59Z","timestamp":1775683739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"alternative-id":["S0960977626000147"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104704","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104704"}}